Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and
folic acid, is effective in the treatment of relapsed or refractory B-cell Non-Hodgkin's
lymphoma (NHL). The study will also investigate the safety of pralatrexate with vitamin B12
and folic acid in this participant population. Additionally, this study includes the
collection of blood samples to investigate the pharmacokinetics (PK) of pralatrexate in this
participant population (PK is the activity of a drug in the body over a period of time,
including how the drug is absorbed, distributed in the body, localized in the tissues, and
excreted from the body).
Phase:
Phase 2
Details
Lead Sponsor:
Spectrum Pharmaceuticals, Inc
Treatments:
10-deazaaminopterin Aminopterin Folic Acid Hydroxocobalamin Vitamin B 12 Vitamin B Complex Vitamins